JLJunbo Liang

Junbo Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Junbo Liang has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoyue Wang

    State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    5 shared publications
  • Dingding Wang

    JST Sarcopenia Research Centre, National Center for Orthopaedics, Beijing Research Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China

    4 shared publications
  • Hong Zhao

    Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    3 shared publications
  • Ran Gao

    State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100005, China

    3 shared publications
  • Bill H. Diplas

    Department of Pathology, Duke University, Durham, North Carolina

    2 shared publications
  • Bing Zhao

    State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Pharmaceutical Sciences, Zhongshan Hospital and School of Life Sciences, Fudan University, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Demoted CD4+ T-cell activity resulted from CTNNB1 mutations resists lenvatinib plus anti-PD1 in HCC

    by Fei Zhao, Kun Chen, Yiqiao Deng, Shaoyan Cheng, Chentong Xiao, Yi Yang, Junbo Liang, Haizhen Lu, Xu Che, Chungui Xu, et al.

    Hepatocellular carcinoma (HCC) patients frequently fail to respond to combined anti-PD1 immunotherapy, though pre-existing neoantigen-specific CD8⁺ T cells within tumor microenvironment are reinvigorated upon PD1 blockaded. Tumor-intrinsic mechanisms driving the therapeutic resistance in HCC remain unclear. Here, we analyzed pretreatment tumor biopsies from 78 advanced HCC patients receiving lenvatinib plus anti-PD1, and found that activation of Wnt/β-catenin signaling was significantly enriched in non-responders (49/78) compared with responders (29/78). Further analyses in 114 NCC-HCCs and 358 TCGA-LIHCs, a paucity of CD4⁺ T cells and mononuclear phagocytes was detected specifically in tumors harboring CTNNB1 mutations affecting the β-TrCP binding motif, particularly D32 mutations, but not in tumors with other Wnt/β-catenin activating alterations. We constructed β-catenin mutants at D32 (D32-mutant), transducing SK-Hep1 HCC cells and inducing murine liver cancers via hydrodynamic tail-vein injection of oncogene vector mixtures. D32-mutant strongly suppressed HCC cell-intrinsic NF-κB activity to repress the production of multiple chemokines and inflammatory cytokines, demoting CD4 + T-cell-mediated antitumor immunity by restraining mononuclear phagocyte infiltration and maturation. In C57BL/6 mice bearing SC4.D32 tumor, deficient in MHC-I mediated CD8 + T-cell-recognition, E7386 addition improved anti-PD1 antitumor effect and augmented lenvatinib plus anti-PD1 efficacy, relating to the enhancement of CD4 + T-cell-mediated antitumor immunity by recovering tumor-intrinsic NF-κB activity to increase tumor infiltration of phagocytes and their communication with CD4⁺ T cells. Thus, potentiating tumor-intrinsic NF-κB activity in mutated CTNNB1 -driven “immune excluded” HCCs could advance anti-PD1 treatment efficacy.

  • Muscle Organoids Frontier: Construction Strategies and Applications of Multi-lineage Muscle Organoids and Multi-organoid Systems

    by Dingding Wang, Lining Xu, Weijia Liu, Zitong Xie, Yuqing Sun, Mingxing Fan, Ling Wang, Quanzhong Ren, Yajun Liu, Junbo Liang, et al.

  • Open Access

    Landscape of Somatic and Age‐Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long‐Read Sequencing

    by Zhewen Wei, Yinghao Cao, Hongchao Liu, Mei Liu, Bolun Zhang, Jianming Ying, Jianqiang Cai, Xinyu Bi, Jianjun Zhao, Jianguo Zhou, et al.

    Hepatocellular carcinoma (HCC) was characterized by a highly complex genome, with structural variations (SVs) playing a significant role in its development. In this study, we employed Oxford Nanopore Technology long‐read sequencing in paired tumor and adjacent normal liver tissues from 74 Chinese HCC patients to thoroughly characterize the landscape of somatic SVs. Our analysis revealed that somatic SVs were more prevalent in hepatitis B virus (HBV)‐related HCC, with chromosome 1 emerging as a major hotspot, and several members of the chromosome 1 open reading frame (C1orf) family genes expression level exhibited significant age‐related difference. Notably, HBV‐related HCC cases exhibited a higher frequency of deletions, particularly among younger ones (≤ 35 years old). In addition, we observed an increased burden of HBV integration events in younger ones. Remarkably, the divergent‐paired related homeobox ( DPRX ) loci was identified as a novel gene for HBV integration in younger patients. Together, these findings delineated the somatic SV landscape in HCC and underscored age‐associated HBV‐related genomic alterations as key pathological features of hepatocarcinogenesis.

  • Open Access

    RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis

    by Yuanyang Wang, Qianyi Yang, Feng Lin, Xiaowei Song, Gang Yang, Dahan Wen, Yingyun Yang, Bicheng Wu, Yunmeng Meng, Ning Zhang, et al.

    Current treatments for pancreatic ductal adenocarcinoma (PDAC) fall short of meeting clinical needs, highlighting the urgent need for a comprehensive understanding of PDAC progression, which involves not only biochemical signals but also essential biomechanical cues. Here, we used a CRISPR-Cas9 screen in an orthotopic xenograft model to explore PDAC dynamics. The RNA binding protein DEAD-box helicase 3X-linked (DDX3X) was identified as a pivotal oncogene and biomechanical checkpoint. Specifically, DDX3X up-regulation in PDAC promoted tumorigenesis and metastasis, primarily through the transcriptional repressor TLE family member 2 (TLE2). Dysregulation of DDX3X in the tumor destabilized TLE2 messenger RNA and therefore disrupted the interaction with KLF4 (KLF transcription factor 4), leading to increased expression of myosin light chain 9 (MYL9). This change remodeled F-actin, enhancing tumor cell traction forces and consequently facilitating tumor metastasis. Targeting the DDX3X-TLE2-MYL9 pathway considerably reduces PDAC progression. This research reveals a promising approach for treating PDAC by focusing on biomechanical cues.


  • Top Cited Papers

    PIEZO1 mechanically regulates the antitumour cytotoxicity of T lymphocytes

    by Ruiyang Pang, Weihao Sun, Yingyun Yang, Dahan Wen, Feng Lin, Dingding Wang, Kailong Li, Ning Zhang, Junbo Liang, Chunyang Xiong, et al.

    The killing function of cytotoxic T cells can be enhanced biochemically. Here we show that blocking the mechanical sensor PIEZO1 in T cells strengthens their traction forces and augments their cytotoxicity against tumour cells. By leveraging cytotoxic T cells collected from tumour models in mice and from patients with cancers, we show that PIEZO1 upregulates the transcriptional factor GRHL3, which in turn induces the expression of the E3 ubiquitin ligase RNF114. RNF114 binds to filamentous actin, causing its downregulation and rearrangement, which depresses traction forces in the T cells. In mice with tumours, the injection of cytotoxic T cells collected from the animals and treated with a PIEZO1 antagonist promoted their infiltration into the tumour and attenuated tumour growth. As an immunomechanical regulator, PIEZO1 could be targeted to enhance the outcomes of cancer immunotherapies.


  • Open Access

    Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma

    by Renxian Wang, Dingding Wang, Xueshan Bai, Jianxun Guo, Songxia Xia, Yuning Cheng, Yani Gu, Qian Wang, Jingjun Nie, Dafu Chen, et al.

    Osteosarcoma is the most common malignant bone tumor, tending to be aggressive and recurrent. The therapeutic development for treating osteosarcoma has been largely hampered by the lack of effective and specific targets. Using kinome-wide CRISPR-Cas9 knockout screens, we systematically revealed a cohort of kinases essential for the survival and growth of human osteosarcoma cells, in which Polo-like kinase 1 (PLK1) appeared as a specific prominent hit. PLK1 knockout substantially inhibited proliferation of osteosarcoma cells in vitro and the tumor growth of osteosarcoma xenograft in vivo. Volasertib, a potent experimental PLK1 inhibitor, can effectively inhibit the growth of the osteosarcoma cell lines in vitro. It can also disrupt the development of tumors in the patient-derived xenograft (PDX) models in vivo. Furthermore, we confirmed that the mode of action (MoA) of volasertib is primarily mediated by the cell-cycle arrest and apoptosis triggered by DNA damage. As PLK1 inhibitors are entering phase III clinical trials, our findings provide important insights into the efficacy and MoA of the relevant therapeutic approach for combating osteosarcoma.


  • Open Access

    Supplementary Figure S3 from Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition

    by Junbo Liang, Hong Zhao, Bill H. Diplas, Song Liu, Jianmei Liu, Dingding Wang, Yan Lu, Qing Zhu, Jiayu Wu, Wenjia Wang, et al.

    Supplementary Figure S3. Validation of ATRX synthetic lethal candidates by RNAi.

  • Open Access

    Supplementary Figure S3 from Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition

    by Junbo Liang, Hong Zhao, Bill H. Diplas, Song Liu, Jianmei Liu, Dingding Wang, Yan Lu, Qing Zhu, Jiayu Wu, Wenjia Wang, et al.

    Supplementary Figure S3. Validation of ATRX synthetic lethal candidates by RNAi.

  • Open Access

    Identification of pathogenic variants in cancer genes using base editing screens with editing efficiency correction

    by Changcai Huang, Guangyu Li, Jiayu Wu, Junbo Liang, Xiaoyue Wang

    Background: Millions of nucleotide variants are identified through cancer genome sequencing and it is clinically important to identify the pathogenic variants among them. By introducing base substitutions at guide RNA target regions in the genome, CRISPR-Cas9-based base editors provide the possibility for evaluating a large number of variants in their genomic context. However, the variability in editing efficiency and the complexity of outcome mapping are two existing problems for assigning guide RNA effects to variants in base editing screens.Results: To improve the identification of pathogenic variants, we develop a framework to combine base editing screens with sgRNA efficiency and outcome mapping. We apply the method to evaluate more than 9000 variants across all the exons ofBRCA1andBRCA2genes. Our efficiency-corrected scoring model identifies 910 loss-of-function variants forBRCA1/2, including 151 variants in the noncoding part of the genes such as the 5′ untranslated regions. Many of them are identified in cancer patients and are reported as “benign/likely benign” or “variants of uncertain significance” by clinicians. Our data suggest a need to re-evaluate their clinical significance, which may be helpful for risk assessment and treatment of breast and ovarian cancer.Conclusions: Our results suggest that base editing screens with efficiency correction is a powerful strategy to identify pathogenic variants in a high-throughput manner. Applying this strategy to assess variants in both coding and noncoding regions of the genome could have a direct impact on the interpretation of cancer variants.


  • Open Access

    The phosphorylation of the Smad2/3 linker region by nemo-like kinase regulates TGF-β signaling

    by Junbo Liang, Yanchi Zhou, Ning Zhang, Dingding Wang, Xiaowen Cheng, Kai Li, Rong Huang, Yan Lu, Hailong Wang, Deqiang Han, et al.